Interim phase-3 trial results show Sputnik V vaccine has 91.6% efficacy
The efficacy was 91.6% after the first dose. Although the study was not designed to assess the efficacy of a single dose regimen, the researchers were able to observe a…
Category: Russia
With hasty approval, India squanders an opportunity to build trust in COVID-19 vaccine
Transparency in the approval process is vital for gaining the trust of people so that they don’t hesitate to take the vaccine. If there is already some degree of anxiety…
Scientists alert Lancet to ‘data inconsistencies’ in the Russian vaccine trial paper
A group of 16 scientists has written an open letter to Dr Richard Horton, editor of The Lancet and authors of the Russia’s Sputnik V novel coronavirus vaccine trial paper,…
Russia’s coronavirus vaccine is safe, elicits immune responses in Phase-1/2 trials
Russia’s Sputnik V vaccines for novel coronavirus have been found to be safe for a period of 42 days and capable of inducing antibody responses in all the 42 participants…
Why Russia’s rushed-up coronavirus vaccine is mired in ethical, safety landmine
Russia registering a vaccine for novel coronavirus even before beginning a Phase-3 trial and promising to begin full-scale production of the vaccine in September to make it available by November…
Editorial: Celestial fireball
Published in The Hindu on March 2, 2013 The 2012 DA14 asteroid tracked in advance did not harm us; it skimmed past nearly 27,600 km from the Earth on February…
Science Chronicle 